We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

95 hedge funds and large institutions have $391M invested in Adamas Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 30 increasing their positions, 27 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

317% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 6

42% more capital invested

Capital invested by funds: $276M → $391M (+$115M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

23% more funds holding

Funds holding: 77 → 95 (+18)

11% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 27

4% less call options, than puts

Call options by funds: $8.72M | Put options by funds: $9.07M

Holders
95
Holders Change
+18
Holders Change %
+23.38%
% of All Funds
2.37%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.1%
New
25
Increased
30
Reduced
27
Closed
6
Calls
$8.72M
Puts
$9.07M
Net Calls
-$346K
Net Calls Change
-$321K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$16.9M
2
KA
Kerrisdale Advisers
Florida
+$14M
3
Macquarie Group
Macquarie Group
Australia
+$13.8M
4
Citadel Advisors
Citadel Advisors
Florida
+$13.7M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$13.5M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$35.9M
2
AC
Armistice Capital
New York
-$7.48M
3
OM
Opaleye Management
Massachusetts
-$5.07M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$5M
5
OTPPB
Ontario Teachers' Pension Plan Board
Ontario, Canada
-$4.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
PPA
26
Parametric Portfolio Associates
Washington
$2.79M +$425K +23,178 +21%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$2.69M +$12.6K +690 +0.5%
MFW
28
Mosaic Family Wealth
Missouri
$2.61M – – –
BOS
29
Bingham Osborn & Scarborough
California
$2.58M – – –
SFM
30
Sphera Funds Management
Israel
$2.44M -$1.47M -80,000 -41%
Fidelity International
31
Fidelity International
Bermuda
$2.43M -$1.2M -65,253 -36%
BAMCO Inc
32
BAMCO Inc
New York
$2.19M – – –
Goldman Sachs
33
Goldman Sachs
New York
$2.15M +$816K +44,492 +78%
State of New Jersey Common Pension Fund D
34
State of New Jersey Common Pension Fund D
New Jersey
$1.98M – – –
EI
35
EAM Investors
California
$1.79M +$1.55M +84,793 New
Deutsche Bank
36
Deutsche Bank
Germany
$1.46M +$935K +51,008 +282%
TCIM
37
TIAA CREF Investment Management
New York
$1.33M +$322K +17,592 +39%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$1.3M -$37.8K -2,064 -3%
Bank of America
39
Bank of America
North Carolina
$1.27M +$1.02M +55,671 +1,349%
BGIM
40
Brandywine Global Investment Management
Pennsylvania
$1.19M +$1.03M +56,283 New
Allianz Asset Management
41
Allianz Asset Management
Germany
$1.14M -$6.07K -331 -0.6%
GL
42
GLG LLC
New York
$1.01M +$878K +47,900 New
Group One Trading
43
Group One Trading
Illinois
$794K +$688K +37,518 New
Fisher Asset Management
44
Fisher Asset Management
Washington
$773K +$669K +36,506 New
Simplex Trading
45
Simplex Trading
Illinois
$762K +$660K +36,024 New
PAM
46
Private Asset Management
California
$720K – – –
CS
47
Credit Suisse
Switzerland
$697K +$603K +32,878 New
Morgan Stanley
48
Morgan Stanley
New York
$652K +$68.7K +3,746 +14%
OPPM
49
Opus Point Partners Management
New York
$635K – – –
HP
50
Hikari Power
Japan
$635K +$550K +30,000 New
1
2
3 4 5

ADMS Hedge Fund Activity: Q3 2017 in Review

95 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2017, worth a combined $391M — up 42% from $276M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ADMS positions and 6 closed out — a net gain of 19 holders — while 30 added to existing stakes and 27 trimmed.

The largest buyer was Millennium Management, adding an estimated $16.9M. The largest seller was Great Point Partners, cutting an estimated $35.9M.

  • 95 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2017, up from 77 in Q2 2017.
  • Funds reported $391M of Adamas Pharmaceuticals stock for Q3 2017, up 42% quarter-over-quarter.
  • 25 funds opened new Adamas Pharmaceuticals positions in Q3 2017 and 6 closed out, a net change of +19 holders.
  • The largest Adamas Pharmaceuticals buyer in Q3 2017 was Millennium Management, an estimated $16.9M added.
  • The largest Adamas Pharmaceuticals seller in Q3 2017 was Great Point Partners, an estimated $35.9M sold.

Based on aggregated 13F filings for Q3 2017.